Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli(Stanford University), Andrea L. Richardson(Johns Hopkins University), Bryan T. Hennessy(Royal College of Surgeons in Ireland), Judy E. Garber(Dana-Farber Cancer Institute), Gordon B. Mills(The University of Texas MD Anderson Cancer Center), Alexander Gutin(Myriad Genetics), Paula D. Ryan(Massachusetts General Hospital), Zoltán Szállási(Semmelweis University), Kristin C. Jensen(Shaanxi Research Association for Women and Family), Daniel P. Silver(Dana-Farber Cancer Institute), Diana Iliev(Myriad Genetics), Kirsten M. Timms(Myriad (Germany)), Nadine Tung(Beth Israel Deaconess Medical Center), Eric P. Winer(University of Vermont), Victor Abkevich(Shaanxi Research Association for Women and Family), Jerry S. Lanchbury(Myriad Genetics), Zaina Sangale(Myriad Genetics), Anne‐Renee Hartman, Joshua T. Jones(Myriad Genetics), Chris Neff(Myriad Genetics), April Greene-Colozzi(Dana-Farber Cancer Institute), William T. Barry(Harvard University), James M. Ford(Palo Alto University), Julia Reid(Shaanxi Research Association for Women and Family), Steven J. Isakoff(Harvard University)
Cited by 1,158